Denise Devore
Research Subjects
Denise Devore has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anna Petryk
Global Medical Affairs, Alexion, AstraZeneca Rare Disease Boston Massachusetts USA
1 shared publication - Dennis Vestergaard Pedersen
Aarhus University
1 shared publication Derek Dunn
Clinical Development, Alexion, AstraZeneca Rare Disease Boston Massachusetts USA
1 shared publication- Fang Sun
Alexion, AstraZeneca Rare Disease
1 shared publication - Francesco Conti
Department of Clinical and Molecular Medicine Sapienza University of Rome Rome Italy
1 shared publication - Gregers Rom Andersen
Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark
1 shared publication
Latest Publications
- Open Access
- 31 December 2025
- Published by Wiley in JIMD Reports
- Vol. 67 (1)
Efzimfotase Alfa Improves Respiratory Capacity in Muscle Tissue From a Mouse Model of HPP
Hypophosphatasia (HPP) is an inherited metabolic disease caused by deficient tissue‐nonspecific alkaline phosphatase (ALP) activity and characterized by skeletal and nonskeletal symptoms, including muscle weakness and fatigue. We hypothesized that mitochondrial respiration is impaired in muscle in HPP, independent of skeletal manifestations, and that the second‐generation ALP enzyme replacement therapy (ERT) efzimfotase alfa improves respiration. Akp2GW −/− mice were used for this purpose. Body weight, bone mineralization, and survival were validated in Akp2GW −/− mice versus Akp2 −/− mice, an established model of HPP. No significant differences were found, validating the Akp2GW −/− model. Respiratory outcomes were measured in skeletal muscle fiber bundles in age‐ and sex‐matched Akp2GW −/− and Akp2GW +/+ (wild‐type) mice; bone mineralization was assessed. Mean maximal respiration and mitochondrial spare respiratory capacity (SRC) in vehicle‐treated Akp2GW −/− mice were 37% and 30% of values from wild‐type mice, respectively, independent of skeletal manifestations. Efzimfotase alfa treatment significantly improved maximal respiration in tissue from Akp2GW −/− mice by 147% versus vehicle ( p = 0.0059) and improved SRC by 262% versus vehicle ( p = 0.0008). Mean maximal respiration and SRC in tissue from efzimfotase alfa‐treated Akp2GW −/− mice were 92% and 107%, respectively, of tissue from wild‐type mice. Cellular ultrastructure of muscle biopsies from people with HPP showed atypical mitochondrial morphology, including branching cristae and dispersed matrix. In a mouse model of HPP, we show that the altered mitochondrial respiration in skeletal muscle is improved by ERT and that HPP is characterized by altered muscle mitochondrial morphology in humans. Together, these data suggest ERT could improve muscular symptoms in HPP.
- 31 December 2025
- Published by Wiley in JIMD Reports
- Vol. 67 (1)
Open AccessEfzimfotase Alfa Improves Respiratory Capacity in Muscle Tissue From a Mouse Model of HPP
Hypophosphatasia (HPP) is an inherited metabolic disease caused by deficient tissue‐nonspecific alkaline phosphatase (ALP) activity and characterized by skeletal and nonskeletal symptoms, including muscle weakness and fatigue. We hypothesized that mitochondrial respiration is impaired in muscle in HPP, independent of skeletal manifestations, and that the second‐generation ALP enzyme replacement therapy (ERT) efzimfotase alfa improves respiration. Akp2GW −/− mice were used for this purpose. Body weight, bone mineralization, and survival were validated in Akp2GW −/− mice versus Akp2 −/− mice, an established model of HPP. No significant differences were found, validating the Akp2GW −/− model. Respiratory outcomes were measured in skeletal muscle fiber bundles in age‐ and sex‐matched Akp2GW −/− and Akp2GW +/+ (wild‐type) mice; bone mineralization was assessed. Mean maximal respiration and mitochondrial spare respiratory capacity (SRC) in vehicle‐treated Akp2GW −/− mice were 37% and 30% of values from wild‐type mice, respectively, independent of skeletal manifestations. Efzimfotase alfa treatment significantly improved maximal respiration in tissue from Akp2GW −/− mice by 147% versus vehicle ( p = 0.0059) and improved SRC by 262% versus vehicle ( p = 0.0008). Mean maximal respiration and SRC in tissue from efzimfotase alfa‐treated Akp2GW −/− mice were 92% and 107%, respectively, of tissue from wild‐type mice. Cellular ultrastructure of muscle biopsies from people with HPP showed atypical mitochondrial morphology, including branching cristae and dispersed matrix. In a mouse model of HPP, we show that the altered mitochondrial respiration in skeletal muscle is improved by ERT and that HPP is characterized by altered muscle mitochondrial morphology in humans. Together, these data suggest ERT could improve muscular symptoms in HPP.
- Open Access
- 13 October 2024
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2415060
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration
The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable domain of a heavy chain only antibody (VHH) that binds properdin (FP) connected via a flexible linker to an N-terminal VHH that binds human serum albumin (HSA). The purified bispecific VHH antibody exhibits an experimental molecular weight average of 27.4 kDa and can be formulated at > 100 mg/mL. Tarperprumig binds tightly to FP and HSA with sub-nanomolar affinity at pH 7.4 and can associate simultaneously with FP and HSA to form a ternary complex. Tarperprumig potently and dose-dependently inhibits to completion in vitro AP-dependent complement C5b-9 formation, AP-dependent hemolysis, and the AP deposition of C3, FP and C9. X-ray crystallography revealed that the isolated FP-binding VHH recognizes the thrombospondin repeat 5 domain of FP, thereby preventing FP from binding to the AP convertase owing to severe steric hindrance. Tarperprumig cross-reacts with cynomolgus monkey FP and serum albumin. In summary, tarperprumig exhibits properties tailored for subcutaneous administration and is currently in clinical development for the treatment of complement AP-related disorders.
- 13 October 2024
- Published by Taylor & Francis in mAbs
- Vol. 16 (1) , 2415060
Open AccessCharacterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration
The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable domain of a heavy chain only antibody (VHH) that binds properdin (FP) connected via a flexible linker to an N-terminal VHH that binds human serum albumin (HSA). The purified bispecific VHH antibody exhibits an experimental molecular weight average of 27.4 kDa and can be formulated at > 100 mg/mL. Tarperprumig binds tightly to FP and HSA with sub-nanomolar affinity at pH 7.4 and can associate simultaneously with FP and HSA to form a ternary complex. Tarperprumig potently and dose-dependently inhibits to completion in vitro AP-dependent complement C5b-9 formation, AP-dependent hemolysis, and the AP deposition of C3, FP and C9. X-ray crystallography revealed that the isolated FP-binding VHH recognizes the thrombospondin repeat 5 domain of FP, thereby preventing FP from binding to the AP convertase owing to severe steric hindrance. Tarperprumig cross-reacts with cynomolgus monkey FP and serum albumin. In summary, tarperprumig exhibits properties tailored for subcutaneous administration and is currently in clinical development for the treatment of complement AP-related disorders.